PURPOSE: Rapid eye movement (REM) sleep deprivation (SD) decreases cerebral sigma-1 receptor expression and causes cognitive deficits. Sigma-1 agonists are cognitive enhancers. Here, we investigate the effect of cutamesine treatment in the REM SD model. PROCEDURES: Sigma-1 receptor occupancy (RO) in the rat brain by cutamesine was determined using 1-[2-(3,4-dimethoxyphenethyl)]-4-(3-phenylpropyl)piperazine ([(11)C]SA4503) and positron emission tomography (PET), and tissue cutamesine levels were measured by ultra performance liquid chromatography (UPLC)-MS. RO was calculated from a Cunningham-Lassen plot, based on the total distribution volume of [(11)C]SA4503 determined by Logan graphical analysis. Cognitive performance was assessed using the passive avoidance (PA) test. RESULTS: Cutamesine at a dose of 1.0 mg/kg reversed REM SD-induced cognitive deficit and occupied 92 % of the sigma-1 receptor population. A lower dose (0.3 mg/kg) occupied 88 % of the receptors but did not significantly improve cognition. CONCLUSION: The anti-amnesic effect of cutamesine in this animal model may be related to longer exposure at a higher dose and/or drug binding to secondary targets.
PURPOSE: Rapid eye movement (REM) sleep deprivation (SD) decreases cerebral sigma-1 receptor expression and causes cognitive deficits. Sigma-1 agonists are cognitive enhancers. Here, we investigate the effect of cutamesine treatment in the REM SD model. PROCEDURES: Sigma-1 receptor occupancy (RO) in the rat brain by cutamesine was determined using 1-[2-(3,4-dimethoxyphenethyl)]-4-(3-phenylpropyl)piperazine ([(11)C]SA4503) and positron emission tomography (PET), and tissue cutamesine levels were measured by ultra performance liquid chromatography (UPLC)-MS. RO was calculated from a Cunningham-Lassen plot, based on the total distribution volume of [(11)C]SA4503 determined by Logan graphical analysis. Cognitive performance was assessed using the passive avoidance (PA) test. RESULTS:Cutamesine at a dose of 1.0 mg/kg reversed REM SD-induced cognitive deficit and occupied 92 % of the sigma-1 receptor population. A lower dose (0.3 mg/kg) occupied 88 % of the receptors but did not significantly improve cognition. CONCLUSION: The anti-amnesic effect of cutamesine in this animal model may be related to longer exposure at a higher dose and/or drug binding to secondary targets.
Authors: Vincent J Cunningham; Eugenii A Rabiner; Mark Slifstein; Marc Laruelle; Roger N Gunn Journal: J Cereb Blood Flow Metab Date: 2009-09-09 Impact factor: 6.200
Authors: Nisha K Ramakrishnan; Anniek K D Visser; Marianne Schepers; Gert Luurtsema; Csaba J Nyakas; Philip H Elsinga; Kiichi Ishiwata; Rudi A J O Dierckx; Aren van Waarde Journal: Psychopharmacology (Berl) Date: 2014-03-18 Impact factor: 4.530
Authors: Petra Schweinhardt; Peter Fransson; Lars Olson; Christian Spenger; Jesper L R Andersson Journal: J Neurosci Methods Date: 2003-10-30 Impact factor: 2.390
Authors: Javad Khodaii; Mostafa Araj-Khodaei; Manouchehr S Vafaee; Dean F Wong; Albert Gjedde Journal: J Nucl Med Date: 2021-06-04 Impact factor: 10.057
Authors: Nisha K Ramakrishnan; Anniek K D Visser; Anna A Rybczynska; Csaba J Nyakas; Paul G M Luiten; Chantal Kwizera; Jurgen W A Sijbesma; Philip H Elsinga; Kiichi Ishiwata; Rudi A J O Dierckx; Aren van Waarde Journal: Mol Imaging Biol Date: 2016-08 Impact factor: 3.488